Please login to the form below

Not currently logged in
Email:
Password:

thalidomide

This page shows the latest thalidomide news and features for those working in and with pharma, biotech and healthcare.

Celgene reaches $9bn agreement to buy Juno

Celgene reaches $9bn agreement to buy Juno

Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation

Latest news

More from news
Approximately 3 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Does safety sell medicines? Does safety sell medicines?

    Who would have thought 50 years ago that thalidomide would be back on the UK market helping patients with life-threatening multiple myeloma - possible due to a risk management programme centered

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics